Mosaic ImmunoEngineering Inc. announced that two research grants totaling $4.3 million from the National Cancer Institute were awarded to the Company's collaborating scientists and their respective academic institutions. The funding will be used for further studies investigating the activity of CPMV, a first-in-class plant virus used to timulate immune responses against cancer. The Company's lead CPMV oncology candidate, MIE-101, is in late-stage preclinical development.